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Martin L Phillips2,3, Alan T Ly1,2,3, Duilio Cascio1,2,3, Michael R Sawaya1,2,3,
David S Eisenberg1,2,3*
1Department of Biological Chemistry, Howard Hughes Medical Institute, UCLA, Los
Angeles, United States; 2UCLA-DOE Institute for Genomics and Proteomics, Los
Angeles, United States; 3Department of Chemistry and Biochemistry, UCLA, Los
Angeles, United States
Abstract Overproduction of immunoglobulin light chains leads to systemic amyloidosis, a lethal
disease characterized by the formation of amyloid fibrils in patients’ tissues. Excess light chains are
in equilibrium between dimers and less stable monomers which can undergo irreversible
aggregation to the amyloid state. The dimers therefore must disassociate into monomers prior to
forming amyloid fibrils. Here we identify ligands that inhibit amyloid formation by stabilizing the
Mcg light chain variable domain dimer and shifting the equilibrium away from the amyloid-prone
monomer.
DOI: 10.7554/eLife.10935.001
Introduction
Amyloid fibrils are protein deposits often associated with disease. These deposits show common
structural and biochemical characteristics, including non-covalent self-complementary fibrils, resis-
tance to proteolysis, insolubility in aqueous solution, binding of thioflavin dye, and generation of a
cross-b X-ray diffraction pattern. The spine of amyloid fibrils, termed a ’steric zipper,’ is built by
paired b-sheets with interdigitating side chains and serves as the scaffold for fibril extension. The
inter-strand and inter-sheet distances give rise to a characteristic cross-b X-ray diffraction pattern of
two perpendicular reflections at ~4.8 and ~10 A˚ (Geddes et al., 1968; Hobbs, 1973; Sipe and
Cohen, 2000; Nelson et al., 2005). Formation of a steric zipper requires the presence of a discrete
peptide segment with an amino acid sequence capable of forming a self-complimentary propagating
structure. Such segments are commonly found as integral parts of globular proteins and trigger
aggregation into amyloid fibrils only upon exposure to solvent through full or partial denaturation
(Nelson et al., 2005).
Cases of systemic light chain amyloidosis (AL), associated with multiple myeloma, were first
described in the mid-19th century; however, the etiology of the disease was not clear. In 1848, Dr.
Bence-Jones discovered the disease-associated substance in urine, though it was only later identified
as immunoglobulin light chains (LC) associated with amyloidosis (Kyle, 2001; 2011; Dahlin and
Dockerty, 1950; Glenner et al., 1970; 1971; Glenner, 1973; Sipe et al., 2014). Systemic AL amy-
loidosis is characterized by overexpression of monoclonal LCs, which are able to form homo-dimers.
Despite renal clearance of excess protein, the full-length LCs or their fragments still form amyloid
fibril deposits in patients’ tissues, most frequently in the heart and kidneys, which result in organ
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failure (Falk et al., 1997; Buxbaum, 1986). Although it is clear this deposition causes organ dysfunc-
tion, much remains to be discovered about the molecular process by which immunoglobulins assem-
ble into amyloid fibrils. It is unknown which peptide segments form steric zippers and how to block
their assembly into the amyloid spine.
LCs are produced by plasma cells and their final amino acid sequence is determined by somatic
recombination (Sakano et al., 1979; Marchalonis and Schluter, 1989). LCs are classified by their
amino acid sequence as either k or l. They consist of two domains, the variable (VL) and constant
(CL), which are connected by a joining segment (J). In patients, amyloid fibrils are found to include
either VLs or full-length LCs (VL-J-CL), yet the ubiquitous presence of VLs indicates that this domain
may be the minimal and essential unit for fibril assembly (Falk et al., 1997; Buxbaum, 1986;
1992; Olsen et al., 1998; Lavatelli et al., 2008; Vrana et al., 2009; Bodi et al., 2009).
The crystal structures of full-length LCs and structures of just their VLs both reveal homo-dimers,
which resemble the light chain and heavy chain hetero-dimer of the antigen-binding fragment (Fab)
of a full antibody. Fab is a hetero-dimer composed of both light and heavy chains, each with con-
stant (CL and CH) and variable (VL and VH) immunoglobulin domains. LC homo-dimers, in which the
VL domain is covalently linked to the CL domain, resemble the quaternary structure of the Fab het-
ero-dimer, and non-covalently linked dimers of only VLs structurally resemble the variable region of
the Fab (VL and VH) (Edmundson et al., 1969; Colman et al., 1977; Firca et al., 1978). The interfa-
ces between the variable domains of physiological hetero-dimers and pathological homo-dimers are
lined with apolar residues encompassing a hydrophobic cavity capable of accommodating small mol-
ecules (Edmundson et al., 1984; 1993).
Our work focuses on a l patient-derived VL homo-dimer named Mcg whose structure and proper-
ties were detailed in pioneering studies by Edmundson and coworkers (Edmundson et al., 1969;
1984; 1993; Firca et al., 1978). The cavity between the two VL domains in Mcg is capable of bind-
ing a wide array of ligands, including synthetic organic molecules and peptides, which form contacts
with the side chains of the dimer cavity. The cavity spans most of the 24 A˚-long dimer interface; it is
cylindrically shaped and can be considered to constitute three sites: A, B and C (Edmundson et al.,
1984). Based on the geometry of the dimer with some deviation from the original nomenclature by
Edmundson et al., we designate side chains of residues Y34, Y93, D97 and F99 on one side of the
cylindrical cavity as the ’A-site,’ S36, Y51, E52, S91 and F101 as the ’B-site,’ and Y38, Q40, V48 and
Y89 as the ’C-site’ (Figure 1). Some ligands bind the cavity in a sequential manner without a distinct
preference for one of the sites. For example, 1-anilinonaphthalene-8-sulfonic acid binds in either the
A or C-sites and can migrate between them, whereas fluorescein binds to both sites with partial
occupancy. Other molecules, such as menadione, preferentially bind to only one of the sites
eLife digest Systemic light chain amyloidosis is a disease that occurs when individuals produce
too much of an immune protein. The excess protein chains normally exist in the body as individual
molecules called “monomers” or in pairs called “dimers,” and they can readily switch between these
two forms. However, the monomers are also prone to forming amyloid fibrils, which are difficult to
break down. Amyloid fibrils are often deposited in the heart and kidneys and can lead to organ
failure and death.
Finding molecules that prevent the formation of amyloid fibrils could help to develop treatments
for amyloidosis. Now, Brumshtein, Esswein et al. have screened 27 compounds to identify those that
stabilize the dimer form of the protein. This would reduce the number of monomers in the body,
and so reduce the number of immune proteins that can form amyloid fibrils.
The experiments identified four compounds that could stabilize the dimers, including one called
methylene blue. Comparing the chemical structures of these compounds with the structures of
drugs approved for medical use identified thirteen drugs. However, follow-up tests showed that only
one, called sulfasalazine, reduced the formation of amyloid fibrils. Neither methylene blue nor
sulfasalazine is likely to have a strong enough effect to treat amyloidosis, but they may serve as
templates for future drug designs.
DOI: 10.7554/eLife.10935.002
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(Edmundson et al., 1984). Regardless of binding location, this demonstrates the dimer cavity is
capable of accommodating various hydrophobic and aromatic ligands.
VLs exist in equilibrium between homo-dimers and amyloid-prone monomers. Experiments con-
ducted in denaturing conditions indicate that reducing the stability of the monomeric state pro-
motes amyloid fibril formation, and mutations that induce dimer disassociation or promote
monomer unfolding increase the propensity to form amyloid fibrils (Bernier and Putnam, 1963;
Kishida et al., 1975; Qin et al., 2007; Wetzel, 1994; Hurle et al., 1994; Brumshtein et al., 2014;
Baden et al., 2008). Likewise, mutations that stabilize the structure of VLs or covalently fix VL dimers
inhibit formation of amyloid fibrils. These results indicate that formation of amyloid fibrils involves
two steps: VL dimer disassociation into monomers followed by partial or full unfolding. The mecha-
nism of amyloid formation also suggests that shifting the equilibrium away from the amyloid-prone
monomer by stabilizing the dimer would hinder formation of amyloid fibrils (Figure 2)
(Bulawa et al., 2012; Bellotti et al., 2000).
Figure 1. Stereo image of the ligand-binding sites of the VL dimer. We designate the A-site in red (residues Y34,
Y93, D97 and F99), B-site in yellow (residues S36, Y51, E52, S91 and F101), and C-site in green (residues Y38, Q40,
V48 and Y89).
DOI: 10.7554/eLife.10935.003
Figure 2. Proposed mechanism for using ligands to hinder the aggregation of immunoglobulin VL s into amyloid
fibrils. VL s are in equilibrium between dimers and monomers in solution. Ligands may be used to stabilize the VL
dimer and therefore shift the equilibrium away from amyloid-prone monomers.
DOI: 10.7554/eLife.10935.004
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The monomer-dimer equilibrium of VLs suggests that systemic AL amyloidosis may be mitigated
by binding ligands to the cavity at the VL dimer interface (Figure 2). This approach proved effective
for transthyretin-related amyloidosis, another type of systemic amyloidosis for which stabilizing the
quaternary state led to the development of therapeutics (Miroy et al., 1996). Upon transthyretin tet-
ramer disassociation into amyloid-prone monomers, it forms amyloid fibrils in an acidic environment.
The binding of thyroxine inhibits disassociation and subsequent amyloid formation (Baures et al.,
1998). Following the same principle, a modified ligand with a disassociation constant in the nano-
molar range prevents transthyretin from forming amyloid fibrils and is effective in vivo.
Here we apply structural and biochemical methods to investigate ligands that hinder amyloid for-
mation by stabilizing the VL homo-dimer. We identify ligands that may serve as prototypes for thera-
pies for treating LC amyloidosis and our results are consistent with a mechanism for amyloidosis that
proceeds via dimer disassociation to amyloid-prone monomers (Qin et al., 2007; Brumshtein et al.,
2014).
Results
Identification of ligands that inhibit formation of amyloid fibrils. Based on the previous work of
Edmundson et al., we screened a panel of 27 hydrophobic and aromatic ligands for an inhibitory
effect on the formation of amyloid fibrils (Figure 3) (Edmundson et al., 1976; 1984; 1993). Such
ligands may stabilize VL dimers and decrease disassociation into amyloid-prone monomers. Varying
concentrations of ligands up to 1 mM were used to evaluate the effect of complexes on formation of
amyloid fibrils. Formation of amyloid fibrils was monitored using both ThT fluorescence assays and
EM micrographs. Molecules that showed an inhibitory effect with concentrations under 1 mM were
8-anilino-1-naphthalene sulfonic acid [5], methylene blue [10], Chicago Sky Blue 6B [14] and Phenol
Red [20] (Figure 3B).
Methylene blue, Chicago Sky Blue 6B, and Phenol Red (10, 14 and 20) were used to search Drug-
Bank for approved biomedical compounds resembling their chemical structures and properties with
a similarity threshold value of 0.3 (Law et al., 2014). The search identified 13 compounds that were
tested for an amyloid inhibitory effect by means of ThT assays and EM analysis (Figure 3C). Of these
13 molecules from DrugBank, only sulfasalazine [34] showed an inhibitory effect on formation of
amyloid fibrils. Among all the molecules tested, including the ligands initially screened and the sub-
sequent approved biomedical compounds, the two that show the most potent effect are methylene
blue [10] and sulfasalazine [34]; both hinder amyloid fibril formation at effective concentrations of 0.1
and 0.5 mM respectively (Figure 4).
Equilibrium dialysis binding of methylene blue and sulfasalazine. Equilibrium dialysis was used to
assess the binding constants of methylene blue and sulfasalazine to Mcg. Measured concentrations
were fit to the corresponding model equations and their curves were represented as binding and
Scatchard plots (Figure 5) (Scatchard, 1949; Spitzer and McDonald, 1956). The constants were
derived from a least squares fit of equations to data and are given in Table 1. Although both methy-
lene blue and sulfasalazine bind to Mcg, the Scatchard plots indicate that binding proceeds through
somewhat different pathways: methylene blue shows positive cooperative binding, signifying at least
two sites with different binding constants, while sulfasalazine shows no cooperativity and suggests
an additional, non-specific binding site (Figure 5). The best fit for the sulfasalazine-binding data was
achieved using a model for two identical, independent binding sites per VL dimer, followed by non-
specific binding.
Crystal structures of methylene blue and sulfasalazine bound to the VL dimer. In the crystal struc-
tures of Mcg with methylene blue and sulfasalazine, the ligands bind at the cavity between the two
VL domains (Figure 6, Table 2). In the structure of Mcg with methylene blue, one ligand is bound to
the A-site of the dimer. This differs from equilibrium dialysis results in solution, which indicate at
least two methylene blue binding sites. The structure of Mcg with sulfasalazine indicates two symme-
try-related molecules bound in the hydrophobic cavity of the dimer with both ligands simultaneously
binding to three sites of the VL dimer cavity.
Effect of ligand binding on quaternary state. We used analytical ultracentrifugation to assess
whether ligand binding shifts the equilibrium of Mcg towards more dimers or whether ligands bind
to monomers as well. The wavelengths used for optical density readings of methylene blue (550 nm)
and sulfasalazine (420 nm) did not overlap with protein absorbance. Distributions of molecular
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weights were fit to the absorbance data, thus permitting detection of only the apparent molecular
weights of the protein in complex with ligand (Figure 7, Table 3). The observed molecular weights
indicate that ligands bind only to VL dimers. For methylene blue, the measured molecular weight
was slightly larger than expected; therefore, we performed an additional ultracentrifugation
Figure 3. Panel of ligands analyzed with ThT assays and EM for their ability to inhibit VL amyloid formation. (A) Preliminary molecules screened. 1. 1,2-
naphthoquinone. 2. 1,4-naphthoquinone. 3. 5-hydroxy-1,4-naphthoquinone. 4. quinone. 5. 8-anilinonaphthalene-1-sulfonic acid. 6. methoxy-2-naphthyl-
propionic acid. 7. dopamine. 8. L-phenylalanine. 9. L-tryptophan. 10. methylene blue. 11. eosin Y. 12. rhodamine 6G. 13. Basic Blue 12. 14. Chicago Sky
Blue 6B. 15. 8-aminonaphthalene-1,3,6-trisulfonic acid. 16. Basic Blue 41. 17. dimenhydrinate. 18. stictic acid. 19. 6-carboxyfluorescein. 20. phenol red.
21. R-(-)-apomorphine. 22. sulforhodamine 101. 23. fluorescein methyleneiminodiacetic acid. 24. rhodamine B. 25. tetracycline. 26. doxycycline. 27. ( )-
epigallocatechin gallate. (B) Molecules showing an inhibitory effect on the formation of amyloid fibrils during the preliminary screen. (C) Molecules
identified in a DrugBank search using the most effective candidates from the preliminary screen and a similarity threshold of 0.3. Search using phenol
red: 28. diethylstilbestrol (0.4), 29. sulindac (0.4), 30. tamoxifen (0.4), 31. acitretin (0.4). Search using Chicago Sky Blue 6B: 32. suramin (0.4), 33.
Bumetanide (0.3), 34. sulfasalazine (0.3), 35. sulfadoxine (0.3), 36. amsacrine (0.3), 37. methotrimeprazine (0.3). Search using methylene blue: 38.
clofazimine (0.3), 39. primaquine (0.3), 40. imiquimod (0.3).
DOI: 10.7554/eLife.10935.005
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meniscus depletion experiment to detect possible monomers. The experiment identified no methy-
lene blue bound to VL monomers.
Figure 4. Thioflavin T fibril formation assays and electron micrographs of Mcg VLs in the presence of various concentrations of methylene blue and
sulfasalazine. Averaged fluorescence readings are based on three repeated ThT assays. Error bars are not shown for clarity. The EM micrographs have a
scale bar of 0.5 mm. (A) Mcg alone. (B) Mcg with various concentrations of methylene blue. (C) Mcg with various concentrations of sulfasalazine. As the
concentration of ligand is increased, the ability of VLs to form amyloid fibrils is hindered, as indicated by a decrease in ThT assay fluorescence and
inability to detect fibrils with EM. The ligand concentration that effectively inhibited amyloid formation in these assays was 500 mM for methylene blue
and 250 mM for sulfasalazine.
DOI: 10.7554/eLife.10935.006
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Discussion
The identification of ligands that inhibit LC amyloid formation by stabilizing the VL dimer has thera-
peutic implications for systemic light chain amyloidosis. By utilizing the known ability of ligands to
bind the hydrophobic cavity of VL dimers, we prevent dimer disassociation into monomers and thus
hinder amyloid formation (Edmundson et al., 1984; 1993). A similar approach was used to design
therapies for transthyretin-related amyloidosis by stabilizing the tetrameric state of the protein
(Miroy et al., 1996). Initial screening for ligands that hinder VL amyloid formation revealed four
ligands showing this effect, with methylene blue as the strongest binding ligand. A subsequent
search in the DrugBank aimed to identify similarly effective ligands that are already approved for
medical use.
Since the emission spectra of ThT partly overlaps with the absorption spectra of the ligands, both
ThT assays and EM analysis were necessary to confirm the ability of the ligands to inhibit amyloid for-
mation. Analysis of electron micrographs and ThT assays indicates that increasing the concentration
of methylene blue or sulfasalazine hinders the formation of amyloid fibrils. One of the molecules
Figure 5. Binding of ligands to Mcg VLs. Binding curves (top) and Scatchard plots (bottom) of ligand binding determined from equilibrium dialysis
experiments. Each curve represents binding equations fit to the data by least squares. Binding constants were derived from the fit equations (see
Table 1). Vertical bars represent the standard errors of the mean from independently repeated experiments. [B], [L], and [U] are bound, total, and
unbound concentrations of ligand in mM. (A) Methylene blue binding to Mcg. Rhombs show means for 3 independent experiments performed with 1.0
mg/ml Mcg. Circles show means for 5 independent experiments performed with 0.5 mg/ml Mcg. Notice the sigmoidal shape of the binding plot and
concave shape of the Scatchard plot indicating cooperative binding. (B) Sulfasalazine binding to Mcg. Rhombs show means for 3 independent
experiments performed with 5.0 mg/ml Mcg. Circles show means for 3 independent experiments performed with 2.5 mg/ml Mcg. Notice the saturated
binding and a down-curving shape of the Scatchard plot indicating one binding constant followed by non-specific binding.
DOI: 10.7554/eLife.10935.007
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from our screen, epigallocatechin gallate, was recently suggested to hinder the formation of amyloid
fibrils, yet in our experiments it did not show any effect (Pelaez-Aguilar et al., 2015).
Though both of the ligands bind Mcg and induce amyloid hindering effects, the mechanism of
binding slightly differs. Methylene blue binds through positive cooperativity. This result indicates the
presence of two binding sites, one strong and one weak, where binding to the second site begins
only after the first site is fully occupied. Scatchard plots for sulfasalazine show that the two specific
binding sites on Mcg are identical with the same disassociation constant and that this specific ligand
binding is followed by non-specific binding.
We addressed the difference in the binding mechanisms of methylene blue and sulfasalazine to
Mcg in solution by crystal structures and analytical ultracentrifugation. The crystal structure of Mcg
with methylene blue shows binding at the A-site of the VL dimer cavity and coordination by the side
chains of residues Y34, Y93, D97 and F99. The crystal belongs to space group P21 with one dimer per
asymmetric unit, and the symmetry between the two VL domains of Mcg is broken by the presence of
a sulfate ion bound to only one of the VL domains (Figure 6A). Analytical ultracentrifugation analysis of
the soluble quaternary state indicates the dimer as the most prevalent form of the complex versus
monomer without a bound ligand (Brumshtein et al., 2014). We also observed a small fraction of
oligomers with molecular weights larger than dimers, as confirmed by the meniscus depletion experi-
ment. The meniscus depletion distributes quaternary states along the path length of the sample cell
during analytical centrifugation, thus verifying which state accounts for the deviation in apparent
Table 1. Disassociation constants of ligands that bind to the Mcg VL dimer.
Ligand
<K1>
[mM] (SEM)
<K2> or KNS
[mM] (SEM) N Binding model
Equations fit
([Y]: bound ligand,
[L]: free ligand,
[R]: receptor)
methylene blue 207 (35) 21 (4) 8 Two positively
cooperative sites
R+L, RL+L , RL2
(1) [Y]=([L]*[R]/K1)*(1+ [L]/K2))
(2) [R]=[R0]/(1+[L]/K1+[L]
2/(K1*K2))
sulfasalazine 698 (105) 21 (8) (non-specific
binding)
6 Two equivalent
+ non-specific sites
R+L , RL
(3) [Y]=[R0]*[L]/(K1+[L]) + KNS*[L]
SEM – standard error of the mean; N – number of independent experiments
KNS – nonspecific binding
DOI: 10.7554/eLife.10935.008
Figure 6. Crystal structures of Mcg binding methylene blue (PDB 5ACM) and Mcg binding sulfasalazine (PDB 5ACL). (A) Mcg and methylene blue.
Methylene blue binds the cavity between the VL domains. The sulfate ion binds in the hydrophobic cavity at S36 and may block the secondary
methylene blue binding site. (B) Mcg and sulfasalazine. Two symmetry-related sulfasalazine molecules bind in the hydrophobic cavity between the VL
domains, simultaneously occupying all three sites: A, B, and C. (C) Overlay of the structures from A and B for comparison and annotation of A-B-C
binding sites.
DOI: 10.7554/eLife.10935.009
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molecular weight. The most significant outcome is the complete absence of soluble monomer in com-
plex with the ligand, which verifies our conjecture that the ligands bind and stabilize dimers. In the
case of sulfasalazine, to confirm binding specifically to soluble dimers, the analytical ultracentrifugation
experiments identified dimers as the only quaternary state of the ligand-bound complex.
The reconciliation of our three experiments on the binding of methylene blue to Mcg VLs sug-
gests blocking of the secondary binding site in the crystals. The three experimental findings are:
cooperative binding of methylene blue as measured by equilibrium dialysis, binding of the ligand to
the A-site in the crystal structure, and the absence of monomeric VL in complex with ligand. Taken
together, these observations indicate that the secondary binding site of methylene blue may not be
available in the crystalline state, but available in solution. Secondary binding to either the B or C-
sites may require conformational changes that are less favorable in crystals or induce the higher-
order assembly of complexes larger than dimers.
The crystal structure of Mcg with sulfasalazine explains why only one disassociation constant for
specific binding was measured. Crystals of the complex belong to space group P21212 with two sym-
metry-related ligands bound per Mcg dimer, and thus one ligand bound per VL in the asymmetric
unit (Figure 6B). Therefore, the equivalence of the two sulfasalazine ligands in the crystal explains
why only one disassociation constant was measured by means of equilibrium dialysis. The crystal
structure shows that each of the sulfasalazine ligands occupy all three A-B-C-sites simultaneously;
each ligand binds to the A and B-sites on one of the VLs composing the dimer, while C-site binding
is on the symmetry-related VL. This contrasts with methylene blue, which is bound only to the A-site.
Despite differences in the exact orientation of the side chains where the ligands bind, both ligands
bind in the cavity of the Mcg dimer (Figure 6C).
Table 2. Statistics of X-ray data collection and atomic refinement. Values in parentheses are for the
outermost shell of data. Each structure was derived from a single crystal.
Mcg-methylene blue
PDB 5ACM
Mcg-sulfasalazine
PDB 5ACL
Space group P21 P21212
Cell dimensions
a, b, c (A˚) 39.2, 31.1, 73.6 31.8, 74.6, 39.3
a, b, g (˚) 90, 90.1, 90 90, 90, 90
Resolution (A˚) 39.2-1.0 (1.07) 29.3-1.5 (1.53)
Rsym (%) 7.2 (59.1) 5.5 (52.9)
I/s(I) 9.8 (2.4) 18.7 (3.7)
Completeness (%) 88.6 (81.8) 97.9 (83.2)
Redundancy 3.5 (3.5) 6.9 (5.9)
No. reflections 259214 107913
Rwork/Rfree (%) 11.1/12.2 15.9/18.7
No. atoms
Protein 1610 845
Ligand/ion 36 33
Water 210 134
Average B-factors (A˚2) 16.8 20.4
R.m.s deviations
Bond lengths (A˚) 0.05 0.02
Bond angles (º) 3.27 2.04
Crystallization
conditions
0.2 M NH4Cl, 2.2 M (NH4)2SO4, 0.5 M methylene blue 0.2 M Tri-potassium citrate, 2.2
M
(NH4)2SO4, 0.5 M sulfasalazine
DOI: 10.7554/eLife.10935.010
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Although our experiments were performed using only VLs rather than full-length LCs, the ligand-
binding site between VLs is maintained in full-length LCs. While full-length LCs are disulfide linked at
Figure 7. Analytical ultracentrifugation data for Mcg with methylene blue and Mcg with sulfasalazine. (A)
Absorbance and residuals for 80 mM Mcg with 100 mM methylene blue at 22,000 rpm. (B) Absorbance and
residuals for 80 mM Mcg with 150 mM methylene blue at 22,000 rpm. (C) Dimer meniscus depletion - absorbance
and residuals for 80 mM Mcg with 100 mM methylene blue at 35,000 rpm. (D) Dimer meniscus depletion -
absorbance and residuals for 80 mM Mcg with 150 mM methylene blue at 35,000 rpm. (E) Absorbance and residuals
for 200 mM Mcg with 300 mM sulfasalazine at 22,000 rpm. (F) Absorbance and residuals for 200 mM Mcg with 500
mM sulfasalazine at 22,000 rpm. Measurements were taken after samples reached equilibrium and the distribution
of protein along the cells did not change. Residuals show the corresponding error of the fit of the model to the
data.
DOI: 10.7554/eLife.10935.011
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their CL C-termini, crystal structures indicate that the conformation of VLs is independent of con-
nected constant domains (Ely et al., 1989; Terzyan et al., 2003; Makino et al., 2007). In full-length
LCs, the joining (J) segment between VLs and CLs provides the flexibility for VLs to maintain the
same hydrophobic cavity as that seen in the VL homo-dimer alone. This indicates the strategy of
using ligands to stabilize the VL dimer and hinder amyloid fibril formation may also be effective for
full-length homo-dimers.
The ability of ligands to hinder the aggregation of VLs into amyloid fibrils by stabilizing VL dimers
indicates a promising approach for treatment of systemic light chain amyloidosis disease. While the
light chain amino acid sequence differs between patients, the characteristic hydrophobic cavity of
the homo-dimer formed by overexpressed LCs is conserved (Bodi et al., 2009; Bork et al., 1994;
Edmundson et al., 1976; Solomon and Weiss, 1995). Although our experiments were performed
using a single VL variant, LCs of both l and k maintain a similar tertiary structure and hydrophobic
cavity (Qin et al., 2007; Wetzel, 1994; Brumshtein et al., 2014; Bellotti et al., 2000; Fink, 1998;
Khurana et al., 2001). This conserved hydrophobic pocket indicates a possible target for designing
medications that inhibit LC amyloidosis. Although methylene blue and sulfasalazine may not bind
tightly enough to be directly repurposed as treatments for the disease, these ligands may serve as
prototypes for development of effective medications. As indicated by the ability of these molecules
to inhibit amyloid fibril formation, this approach may result in alleviated symptoms for systemic light
chain amyloidosis patients.
Materials and methods
Preparation of recombinant proteins
Protein samples were prepared as previously described (Brumshtein et al., 2014). In summary, the
VL of the pathologic LC homo-dimer Mcg was expressed in E. Coli, purified in denaturing conditions,
refolded, and concentrated.
Identification of ligands that impede amyloid fibril formation
Following previous research demonstrating the ability of ligands to bind in the hydrophobic cavity
between the two VL domains of the dimer, aromatic and other hydrophobic ligands were screened
for an inhibitory effect on the formation of amyloid fibrils (Edmundson et al., 1984;1993). Amyloid
formation was monitored with Thioflavin T assays and electron microscopy analysis, and we used
molecules that inhibited amyloid fibril formation at concentrations below 1 mM to search DrugBank
to identify biomedical compounds with a similar structure that would potentially inhibit the formation
of amyloid fibrils (Law et al., 2014). We selected structures in DrugBank with a similarity threshold
of 0.3. Search filters were not applied to any other parameters. We dissolved the identified mole-
cules in either water or 20% DMSO for subsequent use in assays of amyloid formation.
Table 3. Apparent VL molecular weights and ligand binding derived from analytical
ultracentrifugation.
Speed
(rpm)
Concentration of
Mcg (mM) Ligand
Concentration of
ligand (mM)
Apparent molecular
weight (Da)
Oligomer
state
22,000 80 methylene
blue
100 27,342 ± 268* Dimer +
multimer
150 26,507 ± 225* Dimer +
multimer
35,000 80 methylene
blue
100 23,609 ± 212* Dimer
150 23,397 ± 152* Dimer
22,000 200 sulfasalazine 300 21,989 ± 571* Dimer
500 21,821 ± 345* Dimer
*Standard error.
DOI: 10.7554/eLife.10935.012
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Amyloid fibril formation assays
Thioflavin (ThT) assays of Mcg amyloid formation were performed in acidic conditions as previously
described (Bellotti et al., 2000). Assays were conducted in the presence of varying concentrations
of the ligands (1.0, 0.50, 0.25, 0.12, 0.05, and 0.03 mM) at 37˚C and constant 300 rpm shaking with
Teflon balls with 0.125 inch radii as stirrers. ThT fluorescence spectra were recorded at 440/480 nm
excitation/emission wavelengths (Wall et al., 1999).
Electron microscopy (EM)
Samples from the ThT fibril formation assays were diluted with water to 10% v/v and applied onto
copper grids with formvar-carbon coating (Ted Pella, Inc., Redding, CA, Cat. No. 01810). Negative
staining was performed with 2% w/v uranyl acetate and images were collected by means of a Tecnai
T12 electron microscope at 120 kV with a Gatan CCD camera.
Equilibrium dialysis binding
Binding constants of the ligands with Mcg were derived using Rapid Equilibrium Dialysis plates with
a membrane cutoff of 8 kDa (Thermo Scientific Inc., Cat. No. 90006) (Waters et al., 2008). Methy-
lene blue at concentrations ranging from ~1–200 mM with 0.5 and 1.0 mg/ml of Mcg, and sulfasala-
zine at concentrations ranging from ~100–5000 mM with 2.5 and 5.0 mg/ml of Mcg were incubated
for 72 hours with constant agitation in standard laboratory conditions. Following incubation, samples
were collected from the membrane and reference cells and final concentrations were measured by
spectrophotometry.
Crystal structure determination
Co-crystallization trials were set up with a Mosquito micro-crystallization robot, using a solution of
20 mg/ml Mcg with 1 mM methylene blue or sulfasalazine ligands. All crystals appeared in the pres-
ence of sulfate or phosphate anions. Crystals were cryo-protected with 25% glycerol and X-ray data
were collected at the 24-ID-C beamline of the Advanced Photon Source (Mcg-methylene blue) or
with a Rigaku Raxis4++ with a HCT detector (Mcg-sulfasalazine). X-ray diffraction data were proc-
essed with XDS package (Kabsch, 2010). Initial phases were obtained by means of molecular
replacement using PDB 3MCG as the initial model and structures were refined with Refmac5
(Murshudov et al., 1997). Graphics were rendered with PyMol and refined atomic models were
deposited into the Protein Data Bank (PDB) (DeLano, 2002).
Analytical ultracentrifugation
Sedimentation equilibrium experiments were performed on Mcg in the presence of methylene blue
and sulfasalazine. Equilibrium runs were performed at 20˚C in a Beckman Optima XL-A analytical
ultracentrifuge using absorption optics at 500 nm for methylene blue and 420 nm for sulfasalazine.
Samples were at concentrations of 1 mg/ml of Mcg with 100 and 150 mM of methylene blue, and 1
and 2.5 mg/ml of Mcg with 300 and 500 mM sulfasalazine. The concentrations of the protein and
ligands were chosen to obtain optical density readings in the linear range of the spectrophotometer
yet with measurable quaternary state densities of the complexes.
Sedimentation equilibrium profiles were measured at speeds of 10,000, 14,000 and 22,000 rpm in
a An-60 Ti rotor. To validate the deviation of the apparent molecular weight of Mcg with methylene
blue, a set of experiments analyzing the meniscus depletion of the Mcg dimer were performed at
35,000 rpm. The data were fit with a non-linear least squares double exponential fit using the Beck-
man Origin-based software (Version 3.01) (Cohn and Edsall, 1943; Laue et al., 1992).
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